| Psoriasis vulgaris
Zoryve Cream vs Wynzora
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Zoryve vs Wynzora with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWynzora has a higher rate of injection site reactions vs Zoryve based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Wynzora but not Zoryve, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zoryve
Wynzora
At A Glance
Topical
Daily
PDE4 inhibitor
Topical
Daily
Vitamin D3 analog + corticosteroid
Indications
- Psoriasis vulgaris
- Dermatitis, Atopic
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris Apply ZORYVE cream, 0.3%, to affected areas once daily in adult and pediatric patients 6 years of age and older.
Dermatitis, Atopic Apply ZORYVE cream, 0.15%, once daily for patients 6 years of age and older; apply ZORYVE cream, 0.05%, once daily for pediatric patients 2 to 5 years of age.
Psoriasis vulgaris Apply to affected areas once daily for up to 8 weeks; do not use more than 100 g per week; discontinue when control is achieved.
Contraindications
- Moderate to severe liver impairment (Child-Pugh B or C)
—
Adverse Reactions
Most common (>=1%), Plaque Psoriasis Diarrhea, headache, insomnia, nausea, application site pain, upper respiratory tract infection, urinary tract infection
Most common (>=1%), Atopic Dermatitis Headache, nausea, application site pain, diarrhea, vomiting, upper respiratory tract infection, rhinitis, conjunctivitis
Most common (>=1%) Upper respiratory infection, headache, application site irritation
Postmarketing Atrophy, striae, telangiectasias, itching, dryness, hypopigmentation, perioral dermatitis, secondary infection, miliaria, cataracts, glaucoma, increased intraocular pressure
Pharmacology
PDE4 inhibitor; roflumilast and its active metabolite (roflumilast N-oxide) inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP.
WYNZORA Cream combines calcipotriene, a synthetic vitamin D3 analog, and betamethasone dipropionate, a synthetic corticosteroid; the exact mechanisms of their actions in plaque psoriasis are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zoryve
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Wynzora
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
Wynzora
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Wynzora
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Wynzora.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZoryveView full Zoryve profile
WynzoraView full Wynzora profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.